China’s Sinovac is sheltered, says Brazil’s leading research organization
- Post By : Kumar Jeetendra
- Source: Reuters
- Date: 20 Oct,2020
São Paulo’s Butantan Institute, one of Brazil’s leading biomedical research centers, which is carrying out the Stage 3 tests, said the two-dose vaccine, called CoronaVac, was secure in a trial thus far involving 9,000 volunteers.
But Butantan manager Dimas Covas said data on how effective the vaccine is will not be published until the trial is completed on all of the 13,000 volunteers.
“The initial results of the clinical research conducted in Brazil prove that one of all the vaccines tested in the country, CoronaVac is the safest, the one with the very best and most promising rates,” São Paulo Governor João Doria told reporters.
The result is just preliminary and researchers will continue monitoring the participants in the on-going trial, Covas stated. It is the first set of results of Sinovac’s Phase 3 international trials, which are also being conducted in Turkey and Indonesia.
Covas stated there were no severe adverse reactions to the vaccine, with 20 percent of the volunteers reporting moderate pain from the injection while 15% reported headaches after the first dose, falling to 10 percent for the second. Less than 5% reported nausea or tiredness, and even less had muscle aches, ” he said.
São Paulo state health secretary Jean Gorinchteyn said the vaccine appeared to produce protective anti-bodies. The state hopes to obtain regulatory approval for CoronaVac at the end of the year to begin inoculating its population early in 2021, in what could the first vaccination programs in the Americas.
Sinovac desired Brazil as a testing ground because it has been one of the worldwide hotbeds of this virus, although instances are 43% off their peak of almost 70,000 new cases each day in late July.
Brazil has reported more than 5.2 million COVID-19 instances since the pandemic began, the world’s third most-affected nation after the United States and India.
AstraZeneca PLC and Oxford University are nearing an investigation of their UK coronavirus vaccine trial. Pfizer Inc has said it could give an early analysis of its trial this month, and Moderna Inc may announce its results in November. Russia’s Gamaleya Institute may provide an evaluation of its vaccine in the next month.
Competing candidates developed by AstraZeneca and Johnson & Johnson have had their trials stopped in america due to safety problems.
Vaccines are thought to be essential tools to curb the rampaging virus, which has killed over 1 million people globally. Brazil is also hosting a Phase 3 trial for AstraZeneca’s vaccine candidate, while Johnson & Johnson said last month it aims to expand its final-stage human trials .
CoronaVac uses inactivated vaccine technology, a traditional method that uses killed virus that can’t replicate in human cells to activate an immune response.
Experts have warned that the safety of inactivated coronavirus vaccine candidates should be observed over longer periods, as some other inactivated vaccines had led to disease enhancement effect, where vaccine-triggered antibodies, instead of offering protection, could worsen infections when people became exposed to a virus after inoculation.